This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
8/25/2022
Mattias
Interviewer
profitability. That is the headline of the Q2 report from Surgical Science published this morning. To get some facts behind this I have with me the CEO Gisli Hennemark. Welcome.
Gisli Hennemark
CEO
Thank you Mattias.
Mattias
Interviewer
So this headline is intriguing and reflects the numbers that came in higher than analysts' expectations. Net sales amounted to 188 million Swedish kronor and adjusted EBIT landed on 44.3 million Swedish kronor. Can you give us a brief of the quarter and how this was achieved?
You're reading a preview of the SUS.ST Q2 2022 earnings call.
Free account.
Disclaimer